These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11393329)

  • 41. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Wadworth AN; Goa KL
    Drugs; 1991 Dec; 42(6):1018-60. PubMed ID: 1724637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children.
    Calzi A; Grignolo S; Caviglia I; Calevo MG; Losurdo G; Piaggio G; Bandettini R; Castagnola E
    Eur J Pediatr; 2016 Sep; 175(9):1219-1225. PubMed ID: 27558493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia.
    Foster MT
    Pharmacotherapy; 1993; 13(2 Pt 2):45S-50S. PubMed ID: 8474938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Fluoroquinolones--a new and important group of antimicrobial agents].
    Sander J
    Tidsskr Nor Laegeforen; 1992 Jan; 112(3):346-9. PubMed ID: 1553674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of systemic fluoroquinolones.
    Committee on Infectious Diseases
    Pediatrics; 2006 Sep; 118(3):1287-92. PubMed ID: 16951028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Fluoroquinolones, 10 years later].
    de la Blanchardière A; Carbon C
    Rev Prat; 1993 Sep; 43(14):1830-8. PubMed ID: 8310228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The newer fluoroquinolones.
    O'Donnell JA; Gelone SP
    Infect Dis Clin North Am; 2004 Sep; 18(3):691-716, x. PubMed ID: 15308282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gatifloxacin Kyorin Pharmaceutical Co.
    Brown WM
    Curr Opin Investig Drugs; 2000 Sep; 1(1):35-44. PubMed ID: 11249593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quinolones in intracellular infections.
    Pechère JC
    Drugs; 1993; 45 Suppl 3():29-36. PubMed ID: 7689448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones.
    Warren RW
    Pediatr Infect Dis J; 1997 Jan; 16(1):118-22; discussion 123-6. PubMed ID: 9002121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ciprofloxacin in multi-resistant infections in childhood: an audit.
    Khan DM; Bhutta ZA
    J Pak Med Assoc; 1995 Jun; 45(6):147-50. PubMed ID: 7474287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.